Literature DB >> 28672912

Rutin suppresses high glucose-induced ACTA2 and p38 protein expression in diabetic nephropathy.

Chun-Shan Han1, Kai Liu2, Ning Zhang3, Shi-Wen Li3, Hai-Cheng Gao3.   

Abstract

The present study investigated the effect of rutin on high glucose-induced actin, α2, smooth muscle, aorta (ACTA2) and p38 protein expression in diabetic nephropathy (DN). Human mesangial cells were divided into a control group, high glucose-induced mesangial cell group, high glucose + captopril group, and high glucose + rutin group (low, middle and high doses of rutin). Cell viability, adenosine 5'-triphosphate (ATP) content, cell cycle, and ACTA2 and p38 protein expression were examined using MTT assay, ATP assay kit, flow cytometry and immunofluorescence staining in cultured human mesangial cells, respectively. Cell viability, ATP content, and ACTA2 and p38 expression increased significantly in high glucose-induced mesangial cells (P<0.05). However, at concentrations of 0.2, 0.4 and 0.8 µmol/l rutin was able to inhibit high glucose-induced human mesangial cell viability, ATP content, and ACTA2 and p38 expression and improve the cell cycle progression of mesangial cells. In conclusion, ACTA2 and p38 proteins may have important roles in DN. Rutin may inhibit the expression of ACTA2 and p38 and may be utilized in the prevention and treatment of DN.

Entities:  

Keywords:  actin; aorta; diabetic nephropathy; human mesangial cells; p38; rutin; smooth muscle; α2

Year:  2017        PMID: 28672912      PMCID: PMC5488511          DOI: 10.3892/etm.2017.4509

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


Introduction

Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes and a relatively common disease, which is the leading cause of end-stage renal disease (1–4). According to reports, the prevalence rate of DN is 33–40% in type 1 diabetes (5). The prevalence rate of DN is 20–25% in type 2 diabetes (6). Increasing research has focused on the genetics of lesion formation in the coronary artery of patients with type 2 diabetes (7). Actin, α2, smooth muscle, aorta (ACTA2) is located on chromosome 10q(23.3) and is the most abundant α actin content of protein in vascular smooth muscle cells (8). ACTA2 accounts for 40% of the total protein in vascular smooth muscle cells, and 70% of total actin protein (9). Thus, ACTA2 is an important protein required for the contraction of vascular smooth muscle cells. p38 is a key component of mitogen-activated protein kinase-mediated signaling pathways, and is involved in a variety of physiological processes, including inflammation, proliferation and apoptosis (10). Rutin is a drug that has been used clinically for many years for the regulation of cardiovascular disease and for diabetes (11,12). Therefore, the present study aimed to investigate whether rutin is able to inhibit the expression of p38 and ACTA2 and improve the severity of diabetic nephropathy. The protective effects of rutin on diabetic kidney disease were investigated by examining mesangial cell viability, energy metabolism, cell cycle and protein expression with the aim of providing valuable data for the clinical prevention and treatment of DN.

Materials and methods

Materials

ACTA2 (BM1693) and p38 (MK2101) antibodies were purchased from Wuhan Boster Biological Technology, Ltd. (Wuhan, China). G secondary antibodies (AP130P) were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). An MCO-5AC CO2 thermostat incubator was obtained from Sanyo Electric Biomedical Co., Ltd. (Tokyo, Japan).

Cell culture

Glomerular mesangial cells were provided by Jilin University School of Pharmaceutical Sciences (Changchun, China). Glomerular mesangial cells were divided into a control group (PBS washing), high glucose-induced group (incubation with DMEM high glucose to mimic an environment that would induce DN; Invitrogen; Thermo Fisher, Scientific, Inc., Waltham, MA, USA), high glucose + captopril group (0.4 µmol/l, 24 h), and high glucose + low, middle and high rutin groups (0.2, 0.4 and 0.8 µmol/l rutin, respectively). Cells were cultured in DMEM high glucose at 37°C in a humidified atmosphere containing 5% CO2 for 24 h. Cells in the high glucose + rutin groups were treated with rutin for 24 h. Subsequently, mesangial cells were prepared for assays of cell viability, adenosine 5′-triphosphate (ATP) content, cell cycle, and ACTA2 and p38 protein expression levels.

Cell viability assay

A cell viability assay was carried out with an MTT staining kit (Sigma-Aldrich; Merck KGaA), according to the manufacturer's protocol. Results were analyzed using a spectrophotometer (UV2550; Shimadzu Corporation, Kyoto, Japan) at 450 nm.

ATP content

Intracellular ATP was quantified using an ATP Assay Kit (S0026; Biyun Tian Biotechnology Research Institute). Cell suspension (100 µl) was transferred to the wells of a 96-well microplate and ATP Assay reagent (100 µl) was added. The plate was shaken using a plate shaker for 10 min and luminescence was measured using a spectrophotometer (UV2550, 450 nm).

Cell cycle analysis

Glomerular mesangial cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen; Thermo Fisher Scientific, Inc.) in 50-cm2 plates (1×106 cells/well) for 24 h at 37°C then treated with 0.2, 0.4 and 0.8 µmol/l (low, medium and high) rutin. Following incubation for 24 h, the cells were digested with 0.25% trypsin. DNA profiles were evaluated using a flow cytometry station (MACSQuant Analyzer, Miltenyi Biotec, Inc., Cambridge, MA, USA). Histograms or density plots were generated using the MACSQuant digital software.

Immunofluorescence and DAPI staining

Cells were fixed with 4% paraformaldehyde (Sigma-Aldrich; Merck KGaA) for 15 min at room temperature, then washed three times with PBS for 10 min. Cells were incubated with ACTA2 (BM1693) and p38 (MK2101) antibodies (1:200) at 4°C overnight, washed three times for 5 min and subsequently incubated with anti-mouse immunoglobulin G secondary antibodies (1:500; AP130P; Sigma-Aldrich; Merck KGaA) at 4°C for 2 h. DAPI was then used for nuclear staining. Cells were mounted and images were taken using a Nikon eclipse 80i fluorescence microscope (Nikon Corporation, Tokyo, Japan). The protein expression levels of ACTA2 and p38 and apoptotic cell count (DAPI) were analyzed using Image Pro Plus 6.0 software (Media Cybernetics, Inc., Rockbille, MD, USA).

Statistical analysis

All data were obtained from at least three independent experiments and presented as the mean ± standard error of the mean. Statistical comparisons were made using Student's t-tests. Statistical analysis of the data was performed using SPSS v.11.0 for Windows (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Mesangial cell viability

Mesangial cells were treated with different doses of rutin. Results demonstrated that cell viability was significantly increased in the high glucose-induced group at 24 h compared with the control group (P<0.01; Fig. 1). However, cell viability was significantly reduced after treatment with rutin (low, middle and high doses) and captopril (P<0.05) compared with high glucose-induced cells. These results indicated that rutin was able to inhibit the viability of mesangial cells.
Figure 1.

Mesangial cell viability. Data are presented as the mean ± standard error of the mean. **P<0.01 and *P<0.05 vs. M. C, control group; M, high glucose-induced group; P, captopril group; Low, group treated with 0.2 µmol/l rutin; Middle, group treated with 0.4 µmol/l rutin; High, group treated with and 0.8 µmol/l rutin.

ATP content analysis

The present results demonstrated that ATP content was significantly increased in all high glucose-induced mesangial cells compared with the control cells (P<0.05; Fig. 2).
Figure 2.

ATP content of mesangial cells. Data are presented as the mean ± standard error of the mean. **P<0.01. ATP, adenosine 5′-triphosphate; C, control group; M, high glucose-induced group; P, captopril group; Low, group treated with 0.2 µmol/l rutin; Middle, group treated with 0.4 µmol/l rutin; High, group treated with and 0.8 µmol/l rutin.

Flow cytometry was performed following treatment of mesangial cells with 0.2, 0.4 and 0.8 µmol/l rutin for 24 h. Results demonstrated that the cell cycle of mesangial cells changed markedly in the high glucose-induced mesangial cells group. However, the cell cycle progression of mesangial cells improved markedly in cells treated with rutin (Fig. 3; Table I). These results suggested that rutin may affect the regulation of the mesothelial cell cycle.
Figure 3.

Cell cycle analysis in each group of mesangial cells. Cell cycle analysis of the (A) control, (B) high glucose-induced, (C) captopril group and (D) 0.2 (low), (E) 0.4 (middle) and (F) 0.8 µmol/l (high) rutin treatment groups.

Table I.

Cell cycle distribution in each group of mesangial cells.

GroupG1, %G2, %S, %
Control83.603.1313.30
High glucose-induced80.408.2111.40
Captopril81.706.8411.50
Rutin (0.2 µmol/l)85.001.0813.90
Rutin (0.4 µmol/l)82.707.94  9.29
Rutin (0.8 µmol/l)80.807.7911.50

Immunofluorescence staining

As demonstrated in Fig. 4 and Table II, the experimental results indicated apoptotic morphological changes of mesangial cells after 24 h rutin treatment was observed by fluorescence microscopy. Relative to the control group, cell groups treated with rutin exhibited higher numbers of detached cells with round and shrunken morphologies. DAPI nuclear staining also identified signs of mesangial cell apoptosis in the rutin treatment groups.
Figure 4.

Immunofluorescence staining with DAPI. Immunofluorescence images from the (A) control, (B) high glucose-induced, (C) captopril group and (D) 0.2, (E) 0.4 and (F) 0.8 µmol/l rutin treatment groups. Magnification, ×200.

Table II.

ACTA2 and p38 protein expression in each mesangial cell group (%).

GroupNucleusACTA2p38
Control10.27±1.1918.047±0.8112.543±0.24
High glucose-induced25.22±1.75[a]28.41±1.92[a]26.85±0.11[a]
Captopril12.26±0.97[b]22.57±1.36[b]17.05±0.60[b]
Rutin (0.2 µmol/l)17.92±1.79[b]25.61±1.66[b]22.63±0.72[b]
Rutin (0.4 µmol/l)17.84±2.35[b]35.60±2.5319.26±0.65[b]
Rutin (0.8 µmol/l)14.63±1.09[b]20.77±1.40[b]19.93±0.73[b]

Data are presented as the mean ± standard error of the mean.

P<0.05 vs. control group

P<0.05 vs. high glucose-induced group. ACTA2, actin, α2, smooth muscle, aorta.

ACTA2 protein expression

To validate the expression of ACTA2 in mesangial cells, ACTA2 specific fluorescent staining was performed on mesangial cells. The results demonstrated that cells in the control group had uniform chromatin, with a large nucleus and that they maintained integrity of the nuclear envelope. Expression of ACTA2 protein increased significantly in the high glucose group compared with the control (P<0.05; Fig. 5; Table II). The expression of ACTA2 protein decreased significantly in the rutin groups at 24 h compared with the high glucose group (P<0.05; Fig. 5; Table II), with the exception of the middle dose of rutin group.
Figure 5.

ACTA2 protein expression in the different mesangial cell groups. ACTA2 protein expression in the (A) control, (B) high glucose-induced, (C) captopril group and (D) 0.2, (E) 0.4 and (F) 0.8 µmol/l rutin treatment groups. ACTA2, actin, α2, smooth muscle, aorta. Magnification, ×200.

p38 protein expression

To validate the expression of p38 in mesangial cells, p38 specific fluorescent staining was performed on mesangial cells. The results demonstrated that cells in the control group had uniform chromatin, a large nucleus and maintained integrity of the nuclear envelope. The expression of p38 protein increased significantly in high glucose group compared with the control (P<0.05; Fig. 6; Table II). The expression of p38 protein decreased significantly in the rutin groups at 24 h compared with the high glucose group (P<0.05; Fig. 6; Table II).
Figure 6.

p38 protein expression in the different mesangial cell groups. p38 protein expression in the (A) control, (B) high glucose-induced, (C) captopril group and (D) 0.2, (E) 0.4 and (F) 0.8 µmol/l rutin treatment groups. Magnification, ×200.

Discussion

DN is one of the most serious microvascular complications of diabetes (13). Glucose metabolism and renal hemodynamics have an important role in the pathogenesis of DN (14). In the present experiment, high glucose induced the viability of mesangial cells. Rutin inhibited the viability of high glucose-induced mesangial cells. These results indicated that rutin had hypoglycemic effects. ATP is a versatile nucleotide and has an important role in cell biology as a coenzyme that is the ‘molecular unit of currency’ of intracellular energy transfer (15). The present experiment demonstrated that ATP content increased in high glucose-induced mesangial cells, indicating that high glucose may induce a change in ATP content. The content of ATP decreased after intervention with rutin. Therefore, rutin may have a hypoglycemic effect on cells and regulate energy metabolism. ACTA2 exists in birds and mammals. ACTA2 is predominantly distributed in vascular myofibroblastic cells, myoepithelial cells and smooth muscle cells under normal circumstances (16). In the present experiment, the expression of ACTA2 increased in high glucose-induced mesangial cells. Expression of ACTA2 reduced after treatment with rutin. These results indicated that rutin may inhibit the expression of ACTA2 protein and protect against DN. p38 protein kinase is able to promote leukocyte aggregation and activation, regulate the activity of transcription factors and the synthesis of cell factors, and it has an important role in the regulation of inflammatory reactions (17). In the present experiment, the expression of p38 increased in high glucose-induced mesangial cells. p38 expression decreased after treatment with rutin. These results indicated that rutin may inhibit the expression of p38 protein, with protective effects against DN. In conclusion, a diabetic model was successfully induced by high glucose, which promoted glomerular cell viability, increased ATP content, induced changes in the cell cycle, and increased the expression of ACTA2 and p38 proteins. Results suggested that rutin has hypoglycemic effects. Rutin may inhibit the expression of ACTA2 and p38 and may confer protective effects against DN. Rutin may also regulate the expression of p38.
  17 in total

1.  Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections.

Authors:  Dong-Chuan Guo; Hariyadarshi Pannu; Van Tran-Fadulu; Christina L Papke; Robert K Yu; Nili Avidan; Scott Bourgeois; Anthony L Estrera; Hazim J Safi; Elizabeth Sparks; David Amor; Lesley Ades; Vivienne McConnell; Colin E Willoughby; Dianne Abuelo; Marcia Willing; Richard A Lewis; Dong H Kim; Steve Scherer; Poyee P Tung; Chul Ahn; L Maximilian Buja; C S Raman; Sanjay S Shete; Dianna M Milewicz
Journal:  Nat Genet       Date:  2007-11-11       Impact factor: 38.330

Review 2.  Autophagy in diabetic nephropathy.

Authors:  Yan Ding; Mary E Choi
Journal:  J Endocrinol       Date:  2014-10-27       Impact factor: 4.286

3.  Premature ejaculation is associated with glycemic control in Type 1 diabetes.

Authors:  Giuseppe Bellastella; Maria Ida Maiorino; Laura Olita; Elisabetta Della Volpe; Dario Giugliano; Katherine Esposito
Journal:  J Sex Med       Date:  2014-11-26       Impact factor: 3.802

4.  Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats.

Authors:  Sunil K Panchal; Hemant Poudyal; Thiruma V Arumugam; Lindsay Brown
Journal:  J Nutr       Date:  2011-04-20       Impact factor: 4.798

5.  Polysaccharide purified from Ganoderma lucidum induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and p38 mitogen-activated protein kinase pathways.

Authors:  Yu-Li Lin; Yu-Chih Liang; Shiuh-Sheng Lee; Bor-Luen Chiang
Journal:  J Leukoc Biol       Date:  2005-05-13       Impact factor: 4.962

6.  [The effect of urapidil on blood pressure, renal hemodynamics, lipid and glucose metabolism].

Authors:  A F Sanjuliani; V G Fagundes; E A Francischetti
Journal:  Arq Bras Cardiol       Date:  1995-07       Impact factor: 2.000

7.  Rutin alleviates diabetic cardiomyopathy in a rat model of type 2 diabetes.

Authors:  Yong-Bin Wang; Zhi-Ming Ge; Wei-Qiang Kang; Zhe-Xun Lian; Jian Yao; Chang-Yong Zhou
Journal:  Exp Ther Med       Date:  2014-11-26       Impact factor: 2.447

8.  The genetics of diabetic nephropathy.

Authors:  Eoin Brennan; Caitríona McEvoy; Denise Sadlier; Catherine Godson; Finian Martin
Journal:  Genes (Basel)       Date:  2013-11-05       Impact factor: 4.096

Review 9.  New insight into the molecular drug target of diabetic nephropathy.

Authors:  Vivian Soetikno; Wawaimuli Arozal; Melva Louisa; Rianto Setiabudy
Journal:  Int J Endocrinol       Date:  2014-02-04       Impact factor: 3.257

Review 10.  Diabetic kidney disease: from epidemiology to clinical perspectives.

Authors:  Cheol Whee Park
Journal:  Diabetes Metab J       Date:  2014-08       Impact factor: 5.376

View more
  4 in total

1.  Decoding the differentiation of mesenchymal stem cells into mesangial cells at the transcriptomic level.

Authors:  Chee-Yin Wong; Yao-Ming Chang; Yu-Shuen Tsai; Wailap Victor Ng; Soon-Keng Cheong; Ting-Yu Chang; I-Fang Chung; Yang-Mooi Lim
Journal:  BMC Genomics       Date:  2020-07-07       Impact factor: 3.969

Review 2.  Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives.

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Madalina Ioana Anton; Mariana Floria; Petronela Nicoleta Seritean Isac; Loredana Liliana Hurjui; Claudia Cristina Tarniceriu; Claudia Florida Costea; Manuela Ciocoiu; Ciprian Rezus
Journal:  Biomolecules       Date:  2022-09-02

Review 3.  Flavonoids on diabetic nephropathy: advances and therapeutic opportunities.

Authors:  Qichao Hu; Caiyan Qu; Xiaolin Xiao; Wenwen Zhang; Yinxiao Jiang; Zhao Wu; Dan Song; Xi Peng; Xiao Ma; YanLing Zhao
Journal:  Chin Med       Date:  2021-08-07       Impact factor: 5.455

4.  System Pharmacology-Based Dissection of the Synergistic Mechanism of Huangqi and Huanglian for Diabetes Mellitus.

Authors:  Shi-Jun Yue; Juan Liu; Wu-Wen Feng; Fei-Long Zhang; Jian-Xin Chen; Lan-Ting Xin; Cheng Peng; Hua-Shi Guan; Chang-Yun Wang; Dan Yan
Journal:  Front Pharmacol       Date:  2017-10-05       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.